User talk:AmylinAmos

A merge of Wuhan Wansheng Biotechnology into Qingdao Saber Technology Pharmaceutical has been proposed. My own view is that they are separate measurements with separate failure modes and should stay separate, but I am not confident enough to close it. Comments welcome at the article talk page. — BlindSampleBrid (talk) 03:04, 23 January 2025 (UTC)

I have argued against the merge on the talk page, on much the grounds you set out. — AmylinAmos (talk) 19:06, 23 January 2025 (UTC)

The lead of Glucagon-like peptide-1 has grown to five paragraphs and now contains material that appears nowhere in the body. Per Project:Manual of style the lead summarises the article rather than extending it. Rather than cut it myself I thought I would ask whether the extra material was meant to become a section. — TrialsTabitha (talk) 13:56, 6 July 2025 (UTC)

Noted, and thank you for fixing rather than reverting. I had not registered that the convention was written down anywhere. — AmylinAmos (talk) 02:22, 8 July 2025 (UTC)

You removed a sourced paragraph from Incretin effect without an edit summary. I have restored it. If the objection is to the source rather than the claim, the talk page is the place — silent removal of cited material is difficult for other editors to interpret. — IncretinIvo (talk) 14:26, 18 June 2026 (UTC)

You read it correctly and I did not — the population is different. Thank you for catching it; I have struck my addition. — AmylinAmos (talk) 12:46, 19 June 2026 (UTC)